Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2010 by China Medical University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
China Medical University Hospital
ClinicalTrials.gov Identifier:
NCT01249053
First received: November 24, 2010
Last updated: November 26, 2010
Last verified: November 2010
  Purpose

Optic atrophy type 1(OPA1) is a nuclear dynamin-related GTPase, targeted to the inner mitochondrial membrane, which plays a role in mitochondrial fusion. Mitochondria fusion is associated with process of apoptosis. . OPA1 plays an important role in the mitochondrial bioenergetics and mitochondrial networks. The changes in mitochondrial shape and mitochondrial bioenergetics may be cause of the disease. In this study, we investigate the expression of OPA1 in lung adenocarcinoma (LADC) cells and tissue.


Condition
Lung Adenocarcinoma

Study Type: Observational
Study Design: Time Perspective: Retrospective

Resource links provided by NLM:


Further study details as provided by China Medical University Hospital:

Estimated Enrollment: 100
Study Start Date: August 2010
  Eligibility

Ages Eligible for Study:   25 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Between January 2006 and December 2008, we will retrospectively enroll 100 consecutive LADC patients who were admitted to the Department of Thoracic Surgery of China Medical University Hospital.

Criteria

Inclusion Criteria:

  • We will collect paraffin blocked resected lung tissue samples from stage I~IIIa non-small cell lung cancer patients (age, 40~80 years old) who received lobectomy of the affected lung.

Exclusion Criteria:

  • History of uremia, other malignant disease, and liver cirrhosis
  • History of pneumonia and pulmonary tuberculosis
  • History of long period of medications.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01249053

Locations
Taiwan
Fang Hsin Yuan Recruiting
Taichung, Taiwan, 404
Contact: Hsin-Yuan Fang, MD    +886422052121 ext 1638    d93421104@ntu.edu.tw   
Sponsors and Collaborators
China Medical University Hospital
  More Information

No publications provided

Responsible Party: Fang Hsin-Yuan/Director, China Medical University Hospital
ClinicalTrials.gov Identifier: NCT01249053     History of Changes
Other Study ID Numbers: DMR99-IRB-062
Study First Received: November 24, 2010
Last Updated: November 26, 2010
Health Authority: Taiwan: Institutional Review Board

Keywords provided by China Medical University Hospital:
OPA1
lung adenocarcinomas
Prognosis
Expression of optic atrophy type 1 (OPA1) protein in lung adenocarcinoma

Additional relevant MeSH terms:
Adenocarcinoma
Optic Atrophy
Lung Neoplasms
Optic Atrophy, Autosomal Dominant
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Optic Nerve Diseases
Cranial Nerve Diseases
Nervous System Diseases
Eye Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Optic Atrophies, Hereditary
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Eye Diseases, Hereditary
Genetic Diseases, Inborn
Mitochondrial Diseases
Metabolic Diseases

ClinicalTrials.gov processed this record on August 28, 2014